Leap Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Leap Therapeutics CEO'su Doug Onsi, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. in toplam yıllık tazminatı $ 1.53M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43.6% maaş ve 56.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.19% ine doğrudan sahiptir ve bu hisseler € 253.07K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.6 yıl ve 7.8 yıldır.

Anahtar bilgiler

Doug Onsi

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	43.6%
CEO görev süresi	13.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.6yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Doug Onsi'un ücretlendirmesi Leap Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$60m
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$2m	US$669k	-US$81m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	n/a	n/a	-US$82m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$2m	US$637k	-US$55m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$42m
Dec 31 2021	US$2m	US$596k	-US$41m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$513k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$817k	US$400k	-US$33m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$682k	US$400k	-US$23m
Sep 30 2018	n/a	n/a	-US$31m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$3m	US$397k	-US$30m

Tazminat ve Piyasa: Doug 'nin toplam tazminatı ($USD 1.53M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 483.75K ).

Tazminat ve Kazançlar: Doug 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Doug Onsi (55 yo)

13.8yrs

Görev süresi

US$1,534,507

Tazminat

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Onsi	CFO, General Counsel	13.8yrs	US$1.53m	0.19% € 253.1k
Augustine Lawlor	Chief Operating Officer	8.8yrs	US$1.00m	0.013% € 17.5k
Cynthia Sirard	Chief Medical Officer	4.6yrs	US$999.40k	0.013% € 17.2k
Jason Baum	Chief Scientific Officer	1.6yrs	Veri yok	Veri yok
Mark O'Mahony	Chief Manufacturing Officer	4.6yrs	Veri yok	0.013% € 17.2k
Christine Granfield	VP and Head of Regulatory Affairs & Quality	4.3yrs	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: 5MC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Douglas Onsi	CFO, General Counsel	4.7yrs	US$1.53m	0.19% € 253.1k
Christopher Mirabelli	Chairman	13.8yrs	US$744.18k	0.013% € 17.5k
James Cavanaugh	Independent Director	8.8yrs	US$126.62k	0% € 0
Thomas Dietz	Lead Independent Director	8.8yrs	US$188.86k	0% € 0
Nissim Mashiach	Independent Director	7.8yrs	US$118.24k	0% € 0
Joseph Loscalzo	Independent Director	8.8yrs	US$112.12k	0% € 0
William Li	Independent Director	7.8yrs	US$121.62k	0% € 0
Carl Nathan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Richard Schilsky	Independent Director	2.2yrs	US$112.12k	0% € 0
Richard Brian Gaynor	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
David Tuveson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Andrew Nixon	Member of Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

7.8yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 5MC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Leap Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Insufficient new directors

Insufficient new directors

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

First half 2022 earnings released

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

Insufficient new directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020)

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue misses expectations

New 90-day high: €2.18

New 90-day high: €2.00

New 90-day low: €1.27

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day high: €1.84

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - €1.50

New 90-day low - €1.52

Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş